This site is intended for healthcare professionals

Biogen agrees with Samsung Biologics to sell its equity stake in their biosimilar joint venture for up to $2.3 billion.

Read time: 1 mins
Published:29th Jan 2022
Biogen Inc. announced that they have entered into an agreement whereby Samsung Biologics will acquire Biogen’s equity stake in the Samsung Bioepis joint venture for an aggregate consideration of up to $2.3 billion.

Biogen and Samsung Bioepis have built the industry leading anti-TNF portfolio in Europe. Upon the acquisition of Biogen’s stake, the companies will continue with their exclusive agreements, including commercialization of their current portfolio. This includes marketed products Benepali (etanercept), a biosimilar referencing Enbrel, Imraldi (adalimumab), a biosimilar referencing Humira, and Flixabi(infliximab), a biosimilar referencing Remicade. Additionally, Biogen will also retain commercial rights for Byooviz (ranibizumab-nuna), an approved biosimilar referencing Lucentis (ranibizumab), as well as an investigational biosimilar candidate in development, SB15 (aflibercept), a proposed biosimilar referencing Eylea.

Condition: RA/JIA/PsA/AxSpon/Ps/PedPs
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.